PXMD 0.23 PaxMedica, Inc. Common Stock
Range: | 0.065-10.26 | Vol Avg: | 70739 | Last Div: | 0 | Changes: | -0.02 |
Beta: | -0.54 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Fri Aug 26 2022 | Empoloyees: | 6 |
CUSIP: | 70424C104 | CIK: | 0001811623 | ISIN: | US70424C2035 | Country: | US |
CEO: | Mr. Howard J. Weisman | Website: | https://www.paxmedica.com |
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.